{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Chronic+Lymphatic&page=82", "query": { "condition": "Leukemia, Chronic Lymphatic", "page": 82 }, "page_size": 10 }, "pagination": { "page": 82, "page_size": 10, "total_count": 2420, "total_pages": 242, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Chronic+Lymphatic&page=83&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Chronic+Lymphatic&page=81&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T16:00:52.611Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00026429", "title": "Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "denileukin diftitox", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pharmatech Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-10-29T16:00:52.611Z", "location_count": 6, "location_summary": "Pomona, California • Rancho Mirage, California • Saint Charles, Missouri + 3 more", "locations": [ { "city": "Pomona", "state": "California" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "Saint Charles", "state": "Missouri" }, { "city": "Lake Success", "state": "New York" }, { "city": "Myrtle Beach", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00026429" }, { "nct_id": "NCT00439231", "title": "Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georg Aue, M.D.", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 33, "start_date": "2007-02", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2014-01-13", "last_synced_at": "2026-10-29T16:00:52.611Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00439231" }, { "nct_id": "NCT03399773", "title": "Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Biphenotypic Leukemia", "Acute Lymphoblastic Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Hematopoietic and Lymphoid Cell Neoplasm", "Myelodysplastic Syndrome", "Myelodysplastic Syndrome With Excess Blasts" ], "interventions": [ { "name": "Dilanubicel", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Umbilical Cord Blood Transplantation", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspirate", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Electrocardiography", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "10 Years to 65 Years" }, "enrollment_count": 31, "start_date": "2022-05-10", "completion_date": "2027-04-02", "has_results": true, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-10-29T16:00:52.611Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03399773" }, { "nct_id": "NCT03526666", "title": "Ascorbic Acid Levels in MDS, AML, and CMML Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Myelodysplastic Syndromes", "Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "MDS", "AML", "CMML" ], "interventions": [ { "name": "Peripheral blood collection", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Van Andel Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2017-11-01", "completion_date": "2018-10-31", "has_results": false, "last_update_posted_date": "2019-10-03", "last_synced_at": "2026-10-29T16:00:52.611Z", "location_count": 2, "location_summary": "Grand Rapids, Michigan • Wyoming, Michigan", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Wyoming", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03526666" }, { "nct_id": "NCT00096161", "title": "Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Graft Versus Host Disease", "Hodgkin Lymphoma", "Myelodysplastic/Myeloproliferative Neoplasm", "Non-Hodgkin Lymphoma", "Plasma Cell Myeloma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Pentostatin", "type": "DRUG" }, { "name": "Therapeutic Allogeneic Lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 36, "start_date": "2003-05", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2020-01-31", "last_synced_at": "2026-10-29T16:00:52.611Z", "location_count": 4, "location_summary": "Salt Lake City, Utah • Seattle, Washington", "locations": [ { "city": "Salt Lake City", "state": "Utah" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096161" }, { "nct_id": "NCT04260022", "title": "Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myeloid, Chronic", "Myeloid Leukemia", "Chronic Myeloid Leukemia", "Philadelphia Positive Acute Lymphoblastic Leukemia", "B Cell Precursor Type Acute Leukemia" ], "interventions": [ { "name": "Ascentage Pharma HQP1351 bioavailable inhibitor", "type": "DRUG" }, { "name": "Blinatumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascentage Pharma Group Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 242, "start_date": "2020-01-09", "completion_date": "2030-03-31", "has_results": false, "last_update_posted_date": "2025-11-05", "last_synced_at": "2026-10-29T16:00:52.611Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04260022" }, { "nct_id": "NCT01664897", "title": "Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1", "Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A", "Adult Acute Promyelocytic Leukemia With PML-RARA", "Alkylating Agent-Related Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndrome", "Previously Treated Myelodysplastic Syndrome", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2013-05-16", "completion_date": "2018-10-25", "has_results": true, "last_update_posted_date": "2020-01-07", "last_synced_at": "2026-10-29T16:00:52.611Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01664897" }, { "nct_id": "NCT01498445", "title": "An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2012-06-12", "completion_date": "2019-09-24", "has_results": true, "last_update_posted_date": "2020-10-22", "last_synced_at": "2026-10-29T16:00:52.611Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01498445" }, { "nct_id": "NCT06096272", "title": "Using Augmented Reality to Promote Physical Activity in Children With Cerebral Palsy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cerebral Palsy", "Mobile Phone Use", "Pediatric ALL", "Physical Disability", "Physical Inactivity" ], "interventions": [ { "name": "Augment Reality Exergames", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Children's Hospital Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "5 Years to 18 Years" }, "enrollment_count": 30, "start_date": "2024-06-07", "completion_date": "2025-09-01", "has_results": false, "last_update_posted_date": "2025-01-20", "last_synced_at": "2026-10-29T16:00:52.611Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06096272" }, { "nct_id": "NCT00899353", "title": "Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Monoclonal Gammopathy of Undetermined Significance", "Smoldering Multiple Myeloma", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Omega 3 Fatty Acid", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Marshall University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2008-08", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2013-12-12", "last_synced_at": "2026-10-29T16:00:52.611Z", "location_count": 1, "location_summary": "Huntington, West Virginia", "locations": [ { "city": "Huntington", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00899353" } ] }